Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"National Eye Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Scientists Discover New B Cell that Tempers Autoimmunity","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"},{"orgOrder":0,"company":"National Eye Institute","sponsor":"Trethera","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"Trethera Receives $1.6 Million National Eye Institute Grant for Continued Advancement of TRE-515 Optic Neuritis Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"National Eye Institute","sponsor":"Praetego","pharmaFlowCategory":"D","amount":"$0.3 million","upfrontCash":"Undisclosed","newsHeadline":"Praetego Awarded $0.3M by National Eye Institute to Advance Novel Oral Drug for Diabetic Retinopathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"National Eye Institute","sponsor":"iVeena","pharmaFlowCategory":"D","amount":"$0.3 million","upfrontCash":"Undisclosed","newsHeadline":"iVeena Awarded NEI-SBIR Grant for Progressive Myopia Drug Candidate IVMED-85","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by National Eye Institute

    Menu

    National Eye Institute

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              National Eye Institute

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              iVeena Awarded NEI-SBIR Grant for Progressive Myopia Drug Candidate IVMED-85

              Details:

              The grant will be used for the development of IVMED-85, an investigational eyedrop formulation containing copper intended for treatment of pediatric myopia. IVMED-85 will be the first eye drop inducing both scleral and corneal crosslinking for myopia control.

              Lead Product(s): IVMED-85

              Therapeutic Area: Ophthalmology Product Name: IVMED-85

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Recipient: iVeena

              Deal Size: $0.3 million Upfront Cash: Undisclosed

              Deal Type: Funding October 26, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              National Eye Institute

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Praetego Awarded $0.3M by National Eye Institute to Advance Novel Oral Drug for Diabetic Retinopathy

              Details:

              Praetego's NEI grant expands PTG-630 to a third indication and builds upon promising findings in both Alzheimer's disease and diabetic peripheral neuropathy. PTG-630 has demonstrated remarkable potency as an AGE inhibitor.

              Lead Product(s): PTG-630

              Therapeutic Area: Neurology Product Name: PTG-630

              Highest Development Status: Preclinical Product Type: Small molecule

              Recipient: Praetego

              Deal Size: $0.3 million Upfront Cash: Undisclosed

              Deal Type: Funding March 01, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              National Eye Institute

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Trethera Receives $1.6 Million National Eye Institute Grant for Continued Advancement of TRE-515 Optic Neuritis Program

              Details:

              TRE-515 is a novel first-in-class drug, which has been shown to prevent demyelination, and even facilitate remyelination, in multiple demyelinating disease mouse models. Furthermore, the FDA has designated TRE-515 an Orphan Drug in the treatment of ON.

              Lead Product(s): TRE-515

              Therapeutic Area: Oncology Product Name: TRE-515

              Highest Development Status: Phase I Product Type: Small molecule

              Recipient: Trethera

              Deal Size: $1.6 million Upfront Cash: Undisclosed

              Deal Type: Funding October 19, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              National Eye Institute

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NIH Scientists Discover New B Cell that Tempers Autoimmunity

              Details:

              Infusions of purified IL-27 regulatory B cells (I27-Breg ) reduced symptoms in mouse models of multiple sclerosis (MS) and the eye disease autoimmune uveitis. The research suggests the cells may play a role in future human therapies.

              Lead Product(s): I27-Breg

              Therapeutic Area: Ophthalmology Product Name: I27-Breg

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 02, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY